Conference preview: ChinaBio Partnering Forum 2019
The 11th annual ChinaBio Partnering Forum global life science partnering event, which will be held on May 8 and 9 in Shanghai, China, is expected to attract more than 1,400 executives from 500-plus life sciences companies spanning an estimated 25 countries.
Conference preview: BIO-Europe Spring convenes in Vienna
The 13th annual BIO-Europe Spring 2019 global life science partnering event will be held March 25–27 in Vienna, Austria. Guadalupe Rodriguez and Kit Muller of EBD Group report.
The future of precision medicine part 4: diagnosing the diagnostic problem
The development of precision treatments must be complemented by the development of precision diagnostics, as Daniel Lim of Kirkland & Ellis explains.
Conference preview: 11th Pharma & Biotech Patent Litigation
SPCs and trade secrets are just two issues set to be discussed at C5’s 11th Pharma & Biotech Patent Litigation, on February 26 and 27 in Amsterdam. LSIPR reports.
Politics and IP: an unhealthy mix
The political influence on patent rights during Brazil’s general election in October has set a worrying precedent, writes Gabriel Di Blasi of Di Blasi Parente & Associados.
How Mexico applies the Budapest Treaty
Hector Chagoya and Mariana Gonzalez-Vargas of Becerril, Coca & Becerril examine how Mexico applies the Budapest Treaty, which covers microorganisms in the patent process.
Warner-Lambert: the plausibility test for sufficiency of disclosure
In November, the UK Supreme Court ruled that Warner-Lambert’s patent for a second medical use of pregabalin for the treatment of pain is invalid for insufficiency of disclosure. Sheena Linehan of Potter Clarkson explores the lessons for patent drafting.
Mexico: new links between patents and pharmaceuticals
A new facet of Mexico’s linkage system between patents and pharmaceutical drugs raises several questions that necessitate a careful approach from patent assignees and agents, as Mariana Gonzalez-Vargas of Becerril, Coca & Becerril reports.
Generic competition: when one door closes, another opens
With several major drugs set to face generic or biosimilar competition as patent protection expires, LSIPR analyses how well prepared their manufacturers are and how badly their sales may be affected.
Mulling the future for marijuana IP
While cannabis companies in the US can’t protect their brands with federal trademark protection, there are other options for them when seeking IP rights, as LSIPR finds out.
